|
Video: What is a Stock Split?
|
|
SELLAS Life Sciences Group is a biopharmaceutical company developing hematology and oncology therapeutics. Co.'s pipeline consists of multiple mid- to late-stage clinical assets, including its hematology asset, GALE-401, and its cancer immunotherapy programs including NeuVax (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. NeuVax is in clinical trials in breast cancer. GALE-301 and GALE-302 have completed early stage trials in ovarian, endometrial and breast cancers. According to our GALE split history records, GALE has had 1 split. | |
|
GALE (GALE) has 1 split in our GALE split history database. The split for GALE took place on November 14, 2016. This was a 1 for 20 reverse split, meaning for each 20 shares of GALE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as GALE conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the GALE split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into GALE shares, starting with a $10,000 purchase of GALE, presented on a split-history-adjusted basis factoring in the complete GALE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
12/29/2017 |
|
Start price/share: |
$41.60 |
|
End price/share: |
$0.26 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.38% |
|
Average Annual Total Return: |
-74.72% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$62.52 |
|
Years: |
3.69 |
|
|
|
Date |
Ratio |
11/14/2016 | 1 for 20 |
|
|